Dodel, Richard

Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 7,536

Cost of disorders of the brain in Europe 2010

Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology

Mental Health Treatment and AccessHealth Systems, Economic Evaluations, Quality of Life

Cited by 1,723

Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition

Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 830

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease

Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 789

Apolipoprotein E is essential for amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease

Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., Fishman, C. E., DeLong, C. A., Piccardo, P., Petegnief, V., et al. (1999) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 486

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 287

Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease

Riedel, O., Klotsche, J., Spottke, A., Deuschl, G., Förstl, H., Henn, F., Heuser, I., Oertel, W., Reichmann, H., Riederer, P., et al. (2010) · Journal of Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 256

Cognitive impairment in 873 patients with idiopathic Parkinson's disease: Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD)

Riedel, O., Klotsche, J., Spottke, A., Deuschl, G., Förstl, H., Henn, F., Heuser, I., Oertel, W., Reichmann, H., Riederer, P., et al. (2008) · Journal of Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 254

Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease

Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., et al. (2013) · Scientific Reports

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 164

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

Winter, Y., Schepelmann, K., Spottke, A. E., Claus, D., Grothe, C., Schröder, R., Heuss, D., Vielhaber, S., Tackenberg, B., Mylius, V., et al. (2010) · Journal of Neurology

Neurogenetic and Muscular Disorders ResearchHealth Systems, Economic Evaluations, Quality of Life

Cited by 86

Minocycline Blocks 6-Hydroxydopamine-Induced Neurotoxicity and Free Radical Production in Rat Cerebellar Granule Neurons

Lin, S., Wei, X., Xu, Y., Yan, C., Dodel, R., Zhang, Y., Liu, J., Klaunig, J. E., Farlow, M., & Du, Y. (2003) · Life Sciences

Parkinson's Disease Mechanisms and TreatmentsNeuroprotection in Cerebral Ischemia

Cited by 70

Widespread microglial activation in multiple system atrophy

Kübler, D., Wächter, T., Cabanel, N., Su, Z., Turkheimer, F. E., Dodel, R., Brooks, D. J., Oertel, W. H., & Gerhard, A. (2019) · Movement Disorders

Neuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and Treatments

Cited by 61

How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease?

Reed, C., Barrett, A., Lebrec, J., Dodel, R., Jones, R. W., Vellas, B., Wimo, A., Argimon, J. M., Bruno, G., & Haro, J. M. (2017) · Health and Quality of Life Outcomes

Health Systems, Economic Evaluations, Quality of LifeDementia and Cognitive Impairment Research

Cited by 49

Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial

Maier, F., Spottke, A., Bach, J.-P., Bartels, C., Buerger, K., Dodel, R., Fellgiebel, A., Fliessbach, K., Frölich, L., Hausner, L., et al. (2020) · JAMA Network Open

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 46

Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation

Hermann, D. M., Bacigaluppi, M., Bassetti, C. L., Bassotti, G., Boltze, J., Chan, A., Dalkara, T., Denes, A., Diez-Tejedor, E., Dodel, R., et al. (2025) · Exploration of Neuroscience

Health and Medical Research ImpactsAnimal testing and alternatives

Cited by 13